MSMB rs10993707: Understanding Prostate Cancer Risk Variants
The rs10993707 variant is a common genetic change located in the promoter region of the MSMB gene. Research indicates this variant is associated with altered levels of the protein beta-microseminoprotein and variations in prostate cancer risk across diverse populations.
What each genotype means
Higher MSMB expression
This genotype is associated with higher levels of MSMB gene expression in prostate tissue compared to the T allele. Research suggests that individuals with this genotype may have a different risk profile for prostate cancer, though the clinical significance of this association remains a subject of ongoing study.
This genotype is common globally, though frequencies vary significantly by ancestral background.
Intermediate MSMB expression
Carrying one copy of each allele results in intermediate levels of MSMB gene expression compared to the homozygous states. This genotype reflects the common variation found in the promoter region of the MSMB gene, which has been linked in various studies to prostate cancer risk.
This is a very common genotype found across most major global populations.
Lower MSMB expression
This genotype is associated with lower levels of MSMB gene expression in prostate tissue. Some research indicates that this specific variant configuration is linked to altered prostate cancer risk, though it is important to note that genetic risk is complex and influenced by many factors beyond a single variant.
This genotype is observed frequently in diverse populations, consistent with the high minor allele frequency of this variant.
What is rs10993707?
The rs10993707 variant is a single nucleotide polymorphism (SNP) situated in the promoter region of the MSMB gene on chromosome 10. A promoter region is a critical segment of DNA that acts as an on-off switch for gene expression, determining how much of a specific protein a cell produces. Because rs10993707 sits in this regulatory area, it is hypothesized to influence the transcriptional activity of the MSMB gene. By altering the efficiency with which the cell reads the MSMB instructions, this variant can lead to differences in the amount of beta-microseminoprotein (MSP) synthesized by prostate epithelial cells. Scientists study this SNP because it serves as a genetic marker that may help explain why some individuals have different baseline levels of this protein in their blood and seminal plasma, which in turn has been linked to various health outcomes in the prostate gland.
The Role of the MSMB Gene
The MSMB gene provides instructions for creating beta-microseminoprotein, also known as PSP94. This protein is primarily synthesized by the epithelial cells of the prostate gland and is secreted into seminal fluid. It is a member of the beta-microseminoprotein family and is known to possess inhibin-like activity, meaning it can influence hormonal signaling pathways. Beyond its role in the male reproductive system, researchers have investigated its potential function as an autocrine or paracrine factor in other tissues, including breast and uterine tissues. In the context of prostate health, the expression of MSMB is often observed to be decreased in cancerous prostate tissue compared to healthy tissue. Because of this, the protein is considered a potential biomarker for prostate cancer detection and prognosis. Understanding how genetic variants like rs10993707 affect the production of this protein is a major focus of ongoing research into the molecular biology of prostate-related diseases.
Research and Evidence Strength
The association between MSMB variants and prostate cancer has been identified through multiple genome-wide association studies (GWAS). While rs10993707 is frequently cited in the literature alongside other nearby variants like rs10993994, the evidence linking these specific promoter SNPs to prostate cancer risk is considered limited in terms of clinical utility. Research has consistently shown that these variants correlate with circulating levels of beta-microseminoprotein, suggesting a functional mechanism where the variant influences protein expression. However, while the statistical association with cancer risk is robust in many cohorts, it does not mean that carrying a specific genotype guarantees a particular health outcome. Prostate cancer is a complex, multifactorial condition influenced by a combination of genetics, environment, and lifestyle factors. Therefore, this genetic variant should be viewed as one small piece of a much larger biological puzzle rather than a definitive diagnostic tool for predicting individual disease risk.
Population Frequency
The rs10993707 variant is considered a common genetic marker globally. Data from large-scale genomic projects, such as the 1000 Genomes Project and gnomAD, indicate that the minor allele frequency for this SNP typically ranges between 0.35 and 0.45 across major ancestral populations. This high frequency means that a significant portion of the general population carries at least one copy of the variant allele. Because it is so common, it is categorized as a standard genetic polymorphism rather than a rare mutation. The widespread distribution of this variant across different ethnic and geographic groups underscores its role as a common regulatory feature in the human genome. While the frequency is relatively stable, researchers continue to study whether the strength of the association with prostate cancer risk varies across different ancestral backgrounds, as genetic context can sometimes influence how a specific SNP impacts overall health.
What This Information Means for You
Genetic information regarding variants like rs10993707 is intended for educational purposes and should not be used to diagnose or treat any medical condition. If you have received results from a genetic test indicating your genotype for this SNP, it is important to understand that this is not a medical diagnosis. The association between this variant and prostate cancer is statistical, meaning it describes trends across large groups of people rather than predicting the future health of a single individual. You cannot change your genotype, but you can manage your health by maintaining regular screenings and discussing your family history and personal risk factors with a healthcare professional. If you have concerns about prostate health or cancer risk, consult your doctor or a genetic counselor. They can provide personalized guidance based on your complete clinical picture, which is far more informative than any single genetic variant alone.
How common is this variant?
The rs10993707 variant is common globally, with a minor allele frequency of approximately 0.35 to 0.45 across major populations in the 1000 Genomes and gnomAD databases.
Frequently asked questions
Is rs10993707 a diagnostic test for prostate cancer?
No, rs10993707 is not a diagnostic test. It is a genetic variant associated with statistical differences in risk, but it cannot determine if an individual has or will develop prostate cancer.
Can I change my MSMB genotype?
No, your genotype is determined at conception and cannot be changed. Genetic variants are a permanent part of your DNA sequence.
What should I do if I have the TT genotype?
The TT genotype is a common genetic variation. You should continue to follow standard medical guidelines for prostate health screenings and discuss any concerns with your primary care physician.
Does this variant affect other types of cancer?
While MSMB is primarily studied in the context of prostate cancer, some research has explored its expression in other reproductive tissues. Current evidence remains focused on its role in prostate health.
Sources & further reading
Educational information only, last refreshed 9/24/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs10993707?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29